Atara Biotherapeutics, Inc. (ATRA) research

Atara Biotherapeutics, Inc.
ShareXLinkedInReddit
Sector
Healthcare
Industry
Biotechnology
Last price
$8.93
As of

Atara Biotherapeutics, Inc. (ATRA): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-12.

As of . Source: SEC EDGAR filings for ATRA. Method and limitations.

SHARE THIS CARD

Share the ATRA intelligence card

A branded snapshot of ATRA: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion ATRA intelligence card preview
Post to X
LIVE TERMINAL

See ATRA live in the terminal

Track ATRA's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live ATRA terminal, free

Active signals for ATRA

FREE, NO ACCOUNT

Every signal on ATRA, as it fires

You are seeing 5 of 14 signals recorded on ATRA since 2026-05-31.

The five above landed across 2 days. The other 9 were recorded on 2 other days. 10 of the 14 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in ATRA (2026Q2)

Manager / securityMarket value% portfolioQoQ
Point72 Asset Management, L.P.CUSIP 046513206 · 2026Q2$7.9M0.01%,
MILLENNIUM MANAGEMENT LLCCUSIP 046513206 · 2026Q2$146K0.00%,
CITADEL ADVISORS LLCCUSIP 046513206 · 2026Q2$117K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, ATRA

ATRA against its peers

ATRA's operating margin of 29.7% ranks in the 96th percentile of 12 Biotechnology sub-industry peers, fiscal periods ending between 2025-10-31 and 2026-01-31.

MetricATRAPeer medianPercentilen
Revenue FY121M USD1.2M USD9714
Operating margin29.7%-1377.2%9612
Net margin27.1%-725.2%8812
Return on equityn/a-83.2%n/a20
P / E3.5xn/an/a1

Peers (23): NTHI, ANIX, RANI, ONCY, CGTX, PLYX, GUTS, PYPD, SMNR, ACET, RLYB, CRDF, COYA, ICCC, VRCA, NTRB, FBIO, BDTX, CNTB, ALDX, VANI, MIST, GNLX. Left out: HSTC (period gap), TLSA (period gap). Fiscal periods ending between 2025-10-31 and 2026-01-31. Every figure is one full fiscal year read from one annual filing (ATRA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more ATRA signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ATRAand get the insider, 13F, options, and confluence read in one view.

Open the live ATRA terminal, free